Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib in EGFR-mutant pulmonary adenosquamous carcinoma
NCT04354961Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in pulmonary adenosquamous carcinoma (ASC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression Free Survival at 24 months. Status: unknown.
02
Drugs
almonertinib
03
Conditions
pulmonary adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on NCT04354961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354961.